Tuesday 14 July 2026
  • About
  • Contact
  • Login
  • VC & Investment
  • M&A
  • AI
  • Podcasts
  • News
    • Pharmaceutical News
    • Biotechnology News
    • Generics News
    • Biosimilars news
    • In Brief
    • Legal
    • Company Pages
    • In The Boardroom
  • Insights
    • Analysis
    • Special Report
    • Interviews
    • Expert View
    • From Our Correspondent
    • One To Watch Companies
    • Digital Pharma
    • Pharma Leaders
  • Regulatory
    • FDA
    • EMA
    • Pricing, Reimbursement and Access
    • Regulation
    • Government Affairs
    • Trump Administration
  • Therapy Areas
    • Dermatologicals
    • Oncology
    • Neurological
    • Rare Diseases
    • Hematology
    • Cardio Vascular
    • Diabetes
    • Cell And Gene Therapy
  • Conferences
    • JPM Healthcare Conference
    • ESMO
    • ASCO
    • ASH
    • EULAR
    • AAIC
    • EASD
    • Conference News
  • Ones to Watch
  • About
  • Contact
  • Newsletter
  • Sign inSubscribe
Subscribe
  • Home
  • New CEO at LINK Medical

New CEO at LINK Medical

Pharmaceutical
27 January 2025

The board of LINK Medical has announced the appointment of Anders Göransson as the new chief executive (CEO) of the Norwegian contract research organization (CRO).

The company noted that Mr Göransson Anders has over 20 years of diverse experience in the life science industry, he has established an impressive track record of success. He has held prominent positions at leading biotech companies, top-tier management consulting firms, and as CEO of a publicly listed med-tech company.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Try before you buy

 

Free

7 day trial access

Take a Free Trial
  • All the news that moves the needle in pharma and biotech
  • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
  • Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More on this story...

Pharmaceutical
CBO reviews cost of Medicare coverage of obesity meds




More ones to watch >


Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news






Today's issue

Q32 Bio reports top-line results for bempikibart in alopecia areata
Biotechnology
Q32 Bio reports top-line results for bempikibart in alopecia areata
13 July 2026
Biotechnology
Eisai touts latest findings for etalanetug in Alzheimer's
13 July 2026
Pharmaceutical
Pfizer names Danna Breen to lead obesity discovery as Kendra Bence exits
13 July 2026
Biotechnology
Stoke Tx appoints Thomas McCauley as CSO
13 July 2026
Biotechnology
GSK posts positive interim results for Jemperli in rectal cancer
13 July 2026
Pharmaceutical
GHIT Fund commits $18 million to advance six global infectious disease R&D programs
13 July 2026
Biotechnology
Caixa Capital Risc rebrands as Criteria Capital Risc
13 July 2026


Company Spotlight

Q32 Bio
A clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases.


More Features in Pharmaceutical

Pfizer names Danna Breen to lead obesity discovery as Kendra Bence exits
13 July 2026
GHIT Fund commits $18 million to advance six global infectious disease R&D programs
13 July 2026
Industry analysis says innovative medicines deliver six-fold return in Greece
13 July 2026
ChrysCapital’s $159 million Novartis India bid collapses
13 July 2026


The Pharma Letter

39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom


  • About us
  • Contact
  • Subscribe
  • Sponsorship/advertising
  • Company News Directory


  • Terms and Conditions
  • Privacy Policy
  • Twitter
  • Linkedin
Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze